Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

2.360 -0.010 (-0.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
Explore the potential of the best short-squeeze stocks to buy now as companies attempt to prove pessimistic traders wrong. 
Via InvestorPlace
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports on Phase 2A Study Results Regarding Treatment of Premenstrual Dysphoric Disorder
Via Investor Brand Network
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
From Vistagen
Via Business Wire
What's Going On With VistaGen Therapeutics Stock?
VistaGen Therapeutics Inc (NASDAQ: VTGN) shares are trading lower Tuesday. 
Via Benzinga
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Near the Top of Equities by Percentage Gain on 8/7
Via Investor Brand Network
10 Short Squeeze Stocks To Watch: Getty Images, Bitcoin Depot, Blue Apron Holdings And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of traders looking for the next huge move. High short interest and steep borrowing costs are among the... 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), Fuji Pharma Co. Ltd. (TSE: 4554) Announce Exclusive Negotiation Agreement
Via Investor Brand Network
10 Short Squeeze Stocks To Watch: Blue Apron, Getty Images, Black Rifle Coffee And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
From Vistagen
Via Business Wire
10 Short Squeeze Stocks To Watch: Getty Images, Blue Apron, T Stamp, Black Rifle Coffee And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Highly Accomplished Finance Professional as CFO
Via Investor Brand Network
Topics Retirement
Exposures Pension
Vistagen Appoints Cindy Anderson as Chief Financial Officer
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2024 Financial Report, Corporate Update
Via Investor Brand Network
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
From Vistagen
Via Business Wire
Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why AppLovin Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
Gainers PHAXIAM Therapeutics S.A. (NASDAQ: PHXM) shares surged 46.7% to $0.64 in pre-market trading after gaining 6% on Wednesday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders should watch on Thursday morning! 
Via InvestorPlace
$18M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call
Via Investor Brand Network
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
From Vistagen
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?
Vistagen Therapeutics has reported positive Phase 3 trial results for a social anxiety treatment. VTGN stock is skyrocketing as a result. 
Via InvestorPlace
Dow Gains 1%; Tabula Rasa HealthCare Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 350 points on Monday. The Dow traded up 1.02% to 35,423.19 while the NASDAQ rose 0.24% to 13,942.57. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.